- Home
- RLAY vs XXI Comparison
RLAY vs XXI Comparison
Compare RLAY & XXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLAY | XXI |
|---|---|---|
| Founded | 2015 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.6B |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | RLAY | XXI |
|---|---|---|
| Price | $19.76 | $6.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $19.50 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 1.5M |
| Earning Date | 05-05-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,355,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $324.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.44 | N/A |
| 52 Week Low | $3.44 | $4.15 |
| 52 Week High | $21.27 | $11.49 |
Technical Indicators
Market Signals| Indicator | RLAY | XXI |
|---|---|---|
| Relative Strength Index (RSI) | 54.17 | 71.32 |
| Support Level | $18.02 | $5.66 |
| Resistance Level | $20.59 | $6.64 |
| Average True Range (ATR) | 0.93 | 0.29 |
| MACD | -0.09 | 0.26 |
| Stochastic Oscillator | 48.31 | 89.47 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
About XXI Twenty One Capital Inc. Class A Common Stock
Twenty One Capital Inc is engaged in the Bitcoin-related business lines. It engages in two principal activities: actively accumulating Bitcoin and managing its Bitcoin holdings, and commencing development of educational materials and branded content intended to drive increased institutional and retail investor Bitcoin literacy.